In patients with unresectable stage IIIA NSCLC, consolidation immunotherapy after concurrent chemoradiotherapy (the PACIFIC regimen) confers a survival benefit in the population with PD-L1 expression ≥1% (29). This evidence concerns the gene CD274 and non-small cell lung carcinoma.